Cell-based therapy holds great potential to address unmet medical needs and revolutionize
the healthcare industry, as demonstrated by several therapeutics such as CAR-T cell …

Type 1 diabetes therapies that afford tighter glycemic control in a more manageable and
painless manner for patients has remained a central focus of next-generation diabetes …

Engineering hierarchical vasculatures is critical for creating implantable functional thick
tissues. Current approaches focus on fabricating mesoscale vessels for implantation or …

Transplantation of stem cell–derived β (SC-β) cells represents a promising therapy for type 1
diabetes (T1D). However, the delivery, maintenance, and retrieval of these cells remain a …

Islet transplantation is a promising treatment for type 1 diabetes (T1D), yet the low donor
pool, poor islet engraftment, and life-long immunosuppression prevent it from becoming the …

Type 1 diabetes mellitus (T1DM) is a chronic metabolic disease caused by the destruction of
pancreatic β‐cells in response to autoimmune reactions. Shapiro et al. conducted novel islet …

Abstract Type 1 diabetes (T1D) is an autoimmune disease that leads to the loss of insulin-
producing beta cells. Bioartificial pancreas (BAP) or beta cell replacement strategies have …

Fibrin is a promising natural polymer that is widely used for diverse applications, such as
hemostatic glue, carrier for drug and cell delivery, and matrix for tissue engineering. Despite …

Pancreatic islet transplantation still represents a promising therapeutic strategy for curative
treatment of type 1 diabetes mellitus. However, a limited number of organ donors and …

Continuous subcutaneous insulin infusion (CSII) is an essential insulin replacement therapy
in the management of diabetes. However, the longevity of clinical CSII is limited by skin …